35 studies found for:    Emtricitabine / Rilpivirine / Tenofovir disoproxil fumarate OR Complera[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Completed
Has Results
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Condition: HIV-1 Infection
Intervention: Drug: FTC/RPV/TDF
2 Active, not recruiting Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TAF;   Drug: Placebo to match FTC/RPV/TDF;   Drug: FTC/RPV/TDF;   Drug: Placebo to match FTC/RPV/TAF
3 Active, not recruiting FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir
Condition: HIV-1 Infection
Intervention: Drug: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
4 Completed
Has Results
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: EFV/FTC/TDF
5 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: PI;   Drug: RTV;   Drug: NRTIs
6 Active, not recruiting Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TAF;   Drug: Placebo to match EFV/FTC/TDF;   Drug: EFV/FTC/TDF;   Drug: Placebo to match FTC/RPV/TAF
7 Completed A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants
Condition: Healthy
Intervention: Drug: Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC
8 Not yet recruiting HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Conditions: Human Immunodeficiency Virus;   Hepatitis C, Chronic
Interventions: Drug: E/C/F/TAF;;   Drug: Ledipasvir-Sofosbuvir
9 Active, not recruiting A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
Condition: Human Immunodeficiency Virus-type 1 Infection
Interventions: Drug: Rilpivirine;   Drug: Efavirenz;   Drug: Tenofovir disoproxil fumarate;   Drug: Emtricitabine
10 Not yet recruiting Interaction With HIV Antiretroviral Agents
Condition: HIV-DDI
Interventions: Drug: Riociguat (ADEMPAS);   Drug: ATRIPLA;   Drug: COMPLERA;   Drug: STRIBILD;   Drug: TRIUMEQ;   Drug: Antiretroviral protease inhibitor
11 Recruiting Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera
Condition: HIV
Interventions: Drug: Tenofovir disoproxil/emtricitabine/rilpivirine;   Drug: Tenofovir disoproxil/emtricitabine/efavirenz
12 Active, not recruiting Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Condition: HIV
Intervention: Drug: Rilpivirine/Emtricitabine/Tenofovir
13 Unknown  A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
Condition: HIV
Intervention: Drug: tenofovir/emtricitabine/rilpivirine
14 Completed Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Condition: HIV-1 Infection
Intervention:
15 Not yet recruiting SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
Condition: HIV
Intervention: Drug: Eviplera
16 Active, not recruiting Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Rilpivirine;   Drug: Placebo
17 Completed
Has Results
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
Conditions: HIV Infections;   HIV-1;   Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC278;   Drug: Efavirenz
18 Not yet recruiting Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning
Conditions: Neurocognitive Decline;   HIV Associated Neurocognitive Disorder
Intervention: Drug: Eviplera
19 Unknown  Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
Conditions: Impaired Cognition;   Depression/Anxiety;   Poor Quality Sleep;   Quality of Life;   HIV-1 Infection
Interventions: Drug: Immediate switch to TDF/FTC/RPV;   Drug: Switch to TDF/FTC/RPV after 12 weeks
20 Completed Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.
Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men
Intervention: Drug: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Indicates status has not been verified in more than two years